Literature DB >> 15297004

Silent radiological imaging time in patients with brain metastasis.

Kyriaki Mystakidou1, Efstathios J Boviatsis, Andreas T Kouyialis, Konstantinos Voumvourakis, Vassilios Kouloulias, John Kouvaris, Lambros Vlahos.   

Abstract

Cerebral metastasis is a common finding in patients with systemic carcinoma and is an indication for progress of the disease. When brain metastases occur, they lead to a considerable decrease in both survival and the quality of life, in patients who otherwise might be functional. Furthermore, the location, size and number of such lesions, play a decisive role in management and prognosis. Even though early diagnosis and treatment is curative in rare cases, it may lead to a useful remission of the central nervous system (CNS) symptoms, enhance the patient's quality of life and prolong survival. The radiological exams established in the diagnosis of this condition, include computed tomography (CT) scan or magnetic resonance imaging (MRI). In cases of "micrometastatic" disease though, these exams may be pronounced as normal. This retrospective study was performed in patients with advanced systemic disease, who presented with neurological findings of intracranial mass lesion, in the absence of radiological evidence. Early-occurring symptoms were evaluated in accordance to location of the primary disease and follow-up with repetitive MRI scans was performed, in an attempt to confirm the diagnosis and facilitate prompt and appropriate treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15297004     DOI: 10.1016/j.clineuro.2004.01.005

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation.

Authors:  Ho-Taek Song; Elaine K Jordan; Bobbi K Lewis; Wei Liu; Justin Ganjei; Brenda Klaunberg; Daryl Despres; Diane Palmieri; Joseph A Frank
Journal:  J Transl Med       Date:  2009-10-20       Impact factor: 5.531

2.  An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).

Authors:  John Sharp; Vinay Prasad
Journal:  BMC Cancer       Date:  2022-01-16       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.